|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We conclude that a low level of circulating APC in individuals without any of the most recognized thrombophilic defects is a prevalent, independent risk factor for VTE, and that it predisposes to recurrent VTE.
|
11776301 |
2001 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Factor V Leiden thrombophilia is characterized by a poor anticoagulant response to activated protein C (APC) and an increased risk for venous thromboembolism (VTE).
|
29294595 |
2018 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Seven SNPs (F5 rs6025, F2 rs1799963, ABO rs514659, FGG rs2066865, F11 rs2289252, PROC rs1799810 and KNG1 rs710446) with four SNP-SNP interactions contributed to the genetic risk score for VTE, with an AUC of 0.66 (95% CI, 0.64-0.68).
|
25472531 |
2015 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A single factor V gene G-A mutation (Arg506Gln) underlying activated protein C (APC) resistance is a common risk factor for venous thromboembolism.
|
9705241 |
1998 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A total of 685 consecutive patients with at least one episode of VTE and 266 sex- and age-matched healthy controls were screened with regard to activated protein C resistance, protein C, protein S, and antithrombin deficiency, elevated serum levels of Lp(a), and the factor V G1691A, MTHFR C677T, and prothrombin G20210A mutations.
|
11071628 |
2000 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We investigated in case-control studies both biological effects (FVIII levels and activated protein C sensitivity ratio) and clinical associations (venous thromboembolism) of the D1241E change.
|
15735794 |
2005 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The genetic defect of coagulation factor V known as factor V Leiden produces a resistance to degradation by activated protein C (APC) and increases the risk of venous thromboembolism.
|
10590188 |
2000 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Therefore, more data are needed from various populations of patients with venous thromboembolism to help decide which patients will benefit from screening for resistance to APC.
|
8637344 |
1996 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Resistance to activated protein C (APC), which is almost exclusively caused by a point mutation in the factor V gene (FV:Q506 mutation or FV Leiden) is a recently discovered, prevalent risk factor for the occurrence of venous thromboembolism.
|
9763353 |
1998 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The p.R147W mutation, the c.C6152T in exon 7, causing a change in amino acid from arginine to tryptophan of the PROC gene has been reported as a common mutation in Taiwanese populations with venous thromboembolism (VTE).
|
28511552 |
2018 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
High factor VIII plasma levels have been shown to represent a common increased risk for venous thromboembolism (VTE) and may cause an activated protein C (APC) resistance in the absence of the factor V Leiden mutation, but there are no studies specifically aimed to establish if high factor VIII and von Willebrand factor (vWF) concentrations may influence the APC sensitivity ratio (APC-SR) and increase the risk for VTE in the presence of the factor V Leiden mutation.
|
10695766 |
1999 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These complexes as well as circulating APC were also measured in 121 patients with a history of venous thromboembolism (VTE) and 119 matched controls.
|
29448296 |
2018 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Activated protein C (APC) resistance is a common risk factor for venous thromboembolism (VTE) attributed to various mechanisms, including factor V Leiden (FVL) polymorphism.
|
12520697 |
2003 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Several low-frequency genetic mutations, PROS1 p.Lys196Glu in Japanese and PROC p.Arg189Trp and p.Lys193del in Chinese, are significantly associated with increased risk for VTE, with odds ratio more than 2 through the reduced protein C anticoagulant activity.
|
24233386 |
2014 |
|
Venous Thromboembolism
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The THBD 1418T allele is associated with lower soluble TM, both in plasma and in HUVEC-conditioned medium, and with an increase in functional membrane-bound TM in HUVEC, which could explain the increased activated protein C levels and the reduced VTE risk observed in individuals carrying this allele.
|
23520161 |
2013 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The HR2 haplotype was associated with significantly lower APC ratios both in patients with venous thromboembolism and in age- and sex-matched controls.
|
9269773 |
1997 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The endogenous thrombin potential (ETP) showed a striking inter-individual variability among different FV Leiden carriers and, especially when measured in the presence of APC, correlated with VTE risk.
|
24226152 |
2014 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Resistance to activated protein C (APC) is a risk factor for venous thromboembolism also in absence of the FV Leiden mutation.
|
11127861 |
2000 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We conclude that HRT diminishes the efficacy by which APC downregulates in-vitro thrombin formation in a similar fashion to that observed with low-dose oral contraceptives, but the increase in nAPCsr alone is not sufficient to explain the increased risk of VTE associated with use of HRT.
|
11703344 |
2001 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Resistance to activated protein C (APC) is the most common defect found in patients who have venous thromboembolism.
|
9128263 |
1997 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Activated protein C (APC) resistance is related to a single point mutation in the factor V gene (FV:Q506) and appears to be the most common inherited risk factor for venous thromboembolism.
|
9690807 |
1998 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Among them, the factor V (FV) Leiden mutation causes a reduced ability of activated protein C to inactivate activated FV and is the most frequent genetic predisposing factor for venous thromboembolism.
|
19932655 |
2010 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Resistance to activated protein C (APC) has been demonstrated to be a risk factor for venous thromboembolism, but it is not known whether this phenotype is consistent over time.
|
15257714 |
2004 |
|
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Activated protein C (APC) resistance, due to a point mutation in the factor V gene (FV:Q506), is a major risk factor for venous thromboembolism.
|
10235434 |
1999 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We investigated the risk of recurrence of venous thromboembolism in APC resistant patients heterozygous for FV Leiden and compared these patient groups with a group of patients, who had a history of venous thromboembolism, but had neither APC resistance nor the FV Leiden mutation.
|
8815565 |
1996 |